Skip to content

Citaloparam in migraine prophylaxsis

Evaluation of citalopram efficacy in prevention of migraine headaches

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161103030680N9
Enrollment
226
Registered
2018-03-02
Start date
2010-03-20
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Migraine headaches. Condition 2: Migraine headaches. Migraine without aura (common migraine Migraine with aura (classic migraine)

Interventions

Intervention 1: patients in this group take Citalopram thirty milligrams at noon for two months. Dose escalation is gradually within two weeks. Intervention 2: Cotrol group: Patients take placebo whic

Sponsors

Shahed University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age between 18 to 45. Suffering from migraine headaches according to international headache society criteria(IHS). At least three attack of migraine in one month. History of migraine for at least six months.

Exclusion criteria

Exclusion criteria: Suffering from another type of headaches such as Cluster,Tension,.... . History of Asthma, Renal and Heart failure, Depression, any allergic reaction to drugs used in study or similar drugs. Patients who already take drugs for treatment for migraine. History of using anti depressant, anti epileptics, Analgesics, Corticosteroids, Opium, Monoamine Oxidase, and Non steroidal anti inflammatory agents for other reasons.

Design outcomes

Primary

MeasureTime frame
Headache Intensity. Timepoint: At the beginning and at the end of first and second month. Method of measurement: Visual Analougue Scale, And Six points behavioral rating scale BRS-6.;Headache frequency. Timepoint: At the beginning and at the end of second month. Method of measurement: Number of attacks in one month.;Headache duration. Timepoint: At the beginning and at the end of second month. Method of measurement: Average of headaches duration in hour.

Secondary

MeasureTime frame
Drug reactions such as skin redness, pruritus, burning sensation,. Timepoint: Immediately after patient alarm. Method of measurement: Observation and consultation with proper specialist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiamak Afshinmajd

Shahed University

safshinmajd@gmail.com+98 21 5121 3092

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026